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Abstract
The great problem of addictions during the last five decades has been investi-
gated through the behavioral analysis of social determinants involving multiple risk 
factors of initiation and maintenance of legal and illegal substances consumption, 
as well as the search of protective factors that allow preventing and achieving absti-
nence of drug abuse. Currently there is no solution and we are at the crossroads of 
lacking comprehensive attention, since there are treatments focused only on achiev-
ing abstinence and do not pay attention to the physical consequences of substance 
consumption, such as: infectious and non-communicable diseases. It is important 
to treat the addictions problem with a holistic approach, which facilitates access 
to effective medical services, based on scientific evidence, applied to adherence to 
treatment and adapted to patient diagnosis. With the aim of preventing or reducing 
the physical and mental damages that these substances can cause to the health of the 
users, allowing to achieve a better quality of life.
Keywords: addictions, behavior analysis, harm reduction, adherence to treatment, 
comprehensive attention
1. Introduction
Regarding addictions of psychoactive substances, there are multiple definitions 
since it is a multifactorial phenomenon ranging from the moment of the vital 
development in which the subject is, in which the gender influences the process of 
addition, both physically and socially, up to the pattern of consumption, the type 
of substance ingested, the route of administration, among others. However, one 
of the main characteristics of addiction is that it generates changes at a functional 
level in the brain by altering the reward and self-control systems [1]. According to 
the World Health Organization the addiction is a physical and psycho-emotional 
disease, related to a set of signs and symptoms, in which biological, genetic, psy-
chological and social factors are compromised [2]. Considering that over the years 
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new substances producing greater damage to consumers’ health [3] have emerged, 
the WHO has made changes to the classification of substance abuse disorders, in 
order to improve the prevention and treatment of these problems, these modifica-
tions will be reflected in the CIE-11, which is expected to take effect in January 
2022. So far, one of the effective models to follow in the intervention of addictions is 
the Harm Reduction to improve the quality of life of the substance abusers, with or 
without achieving abstinence, but improving physical and mental health [4].
2. Global epidemiology
Inequality at a global level represents a social problem that influenced the 
phenomenon of drug abuse, which has experienced a serious growth, since only in 
a decade the number of people abusing drugs increased by 30% worldwide, from 
2009 with 210 million people to 2019 with 271 million consumers of psychoac-
tive substances, representing 5.5% of the population between 15 and 64 years 
of age, of which 17 million abusers suffer from infectious diseases such as HIV/
AIDS, Tuberculosis and Hepatitis C; in the latter, the main cause was the increase 
of “opioids” consumers, with approximately 53.4 million people consuming it 
worldwide, being the main responsible for the majority of the 585,000 deaths; in 
addition of the lost years of healthy life due to disabilities entitled to drug abuse, 
with about 42 million years of healthy life [5] (Cited [6]). Besides, an alarming fact 
are respiratory diseases, cardiovascular pathologies, as well as cancer associated 
with drug abuse, without undermining of deaths due to injected drugs overdose, 
with a higher risk of suicide, in addition to psychiatric comorbidities; being a focus 
of attention for health systems in the world since only 1 in 6 drug abusers receives 
medical treatment [7].
In America, the consumption of abused substances is not less alarming, 
considering that the start of the consumption of any psychoactive substance, 
including alcohol and tobacco, starts during high school and it is decreasing even 
further. An important fact in the continent is the systematic decrease shown by 
the use of tobacco over time, probably due to the creation of the WHO Framework 
Convention on Tobacco Control arising from the need to combat this pandemic in 
2003 [8] and having a positive impact on the legislation of its use worldwide. In 
the America continent, tobacco shows decreases in its use in most of the countries 
monitoring it, as is the case in Chile, even with the highest level, going from 44 
to 33.4% from 2000 to 2016 in the consumption of the last month; but in terms 
of alcohol consumption, there is a decrease in consumers but those that exist are 
taking more and more [9]; in the case of illegal drugs, trends in use are increasing, 
especially cannabis and cocaine. These increases in consumption have also been 
identified in other substances, such as new psychoactive substances (NPS), opioids 
and benzodiazepines, which produce new challenges for the treatment of patients 
with dependency, for public health and drug policies in general [10].
3. Epidemiology in Mexico
In Mexico, poppy cultivation had a 21% increase from 2016 to 2017, keeping 
the country in third place worldwide in its production [6], mainly in the “Golden 
Triangle” formed by Sonora, Durango and Chihuahua, north of Nayarit and the 
state of Guerrero, which responds to the socioeconomic situation of poverty in the 
population [7]. Our country has become the main distributor of the United States of 
America with 86% of the total of this drug [11].
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According to the National Survey of Drug, Alcohol and Tobacco Consumption 
(ENCODAT) 2016–2017 [12], alcohol is the most consumed and 1.8 million people 
in the country already have dependence; while in the population from 12 to 65 years 
old, the excessive consumption of alcohol increased from 12.3% in 2011 to 19.8% 
in 2016.
Tobacco is the second most consumed psychoactive substance; its prevalence in 
the population from 12 to 65 years old remained stable between 2011 and 2016 with 
17 and 17.6%, respectively [12].
The consumption of any illegal drug increased from 7.2% in 2011 to 9.9% in 
2016, the preferred drugs abused at some time in life continue to be marijuana 
(8.6%) and cocaine (3.5%) [12]. The use of illicit drugs (marijuana, cocaine, 
heroin), substances of abuse (solvents and inhalants) and non-prescription drugs 
(stimulants, depressants), as well as new psychoactive substances, show a lower 
prevalence compared to tobacco and alcohol statistics. However, the seriousness of 
the matter is the severe damage they generate in the individual health, with implica-
tions for family members, the community and society in general, as it is associated 
with greater emphasis on insecurity and violence problems [13].
Regarding medical care, in the Report on the situation of drug abuse in Mexico and 
its comprehensive care 2019, from 2010 to 2017 of the 22,856 deaths directly related 
to drug abuse, the largest number with 21,920 are caused by the consumption of 
alcohol, this is the reason why it continues to be the main drug for which attention is 
requested in medical emergencies, followed by the consumption of cocaine, volatile 
solvents and marijuana. Among the diseases prior to admission due to medical 
emergency under the influence of a drug, the appearance of the following were 
mainly reported: musculoskeletal condition, alcoholic/substance psychosis, diabe-
tes mellitus, gastritis, cirrhosis and hypertension. As relevant data in the last deaths 
register of 2017, in our country 2597 people died, of which the highest percentage of 
deaths were between 30 and 49 years of age [14] which are one of the most produc-
tive stages in the lives of human beings, reflecting the lack of effective educational 
activities and campaigns for the prevention and early and timely detection of condi-
tions to guide consumers regarding these chronic degenerative non-communicable 
diseases (NCDs) that represent a serious problem for public health in Mexico. 
Only in 2016, two of the main health care institutions in our country, Instituto 
Mexicano del Seguro Social (IMSS) and Instituto de Servicio y Seguro Social de los 
Trabajadores del Estado (ISSSTE), together allocated 31.4% of their budget for the 
attention of diseases such as: diabetes, hypertension, renal impairment and cancer 
[15], being mainly those of greater demand, combined with the low budget that 
the Mexican health system has received and the lack of specialized coverage that 
prevents it from reaching poorer populations.
4. Psychosocial determinants of addictions and epigenetics
The coverage in universal health is a worldwide problem. The burden of a dis-
ease is observed in disadvantaged groups resulting in disability at a very young age. 
The dynamics in the social hierarchy and the social flow of the disease are the bases 
on which the Social Determinants of Health (SDH) model is based, explaining the 
majority of inequalities in and between countries when directing interventions in 
the structural determinants and intermediates underlying health inequity: the for-
mer includes the political and economic context where social hierarchical patterns 
originate, modify and maintain within cultural norms and values; these determi-
nants shape the health of the individuals based on their social position, gender, age, 
employment, race and ethnic group, income, and education; while the intermediate 
Behavioral Pharmacology - From Basic to Clinical Research
4
determinants are the means by which the structural determinants operate, allow-
ing the exposure to conditions damaging the health of the subject such as: housing 
quality, physical work environment, social support networks, healthy lifestyles, 
genetic factors, social cohesion and the structure of the health system [16, 17].
In Mexico, based on measurements carried out by the “Consejo Nacional de 
Evaluación de la Política de Desarrollo Social” (CONEVAL), some of the social 
determinants show that 52.4 million people are in poverty, which represents 41.9% 
in 2018 compared to 44.4% in 2008. On the other hand there are 9.3 million people 
in extreme poverty (7.4%) and 37.7 million vulnerable people due to social depriva-
tions, whose main indicators of the total Mexican population include: educational 
lag (16.9%), access to health services (16.2%) access to social security (57.3%), 
access to food (20.4%), housing quality and spaces (11.1%) and access to basic 
housing services (19.8%) [18].
Therefore the social determinants describe addictions as a public health problem 
caused by the lack of a public health policy. The economic and basic education 
inequality, as structural determinants, hinder the development of all the physical 
and intellectual potential of people, since these would have to operate as protec-
tive factors in society; therefore, their absence affects and impacts directly on the 
intermediate determinants, which are distorted, when observed without a basic 
system in the health condition, in the family, culture and nutrition of the popula-
tion to name the most important [19].
Consequently, addressing the risk factors fills the gaps that the traditional medi-
cal model has left in the search for the causes related to NCD and that will prevent 
its progress. The use of this concept has its importance and historical development 
in medicine with the improvement of techniques in the treatment of infectious 
diseases based on microbial theory, considering that humanity has gone through 
an epidemiological transition, in which the increase and appearing of non-com-
municable diseases, such as cardiovascular, cancer, chronic obstructive pulmonary 
disease and diabetes, cannot be treated as infectious diseases were treated, where 
there was a pathogen, because the causes of NCDs are multifactorial, among which 
the consumption of addictive substances, physical inactivity and deficit in eating 
behavior stand out [20].
Considering that the causal relationship with the health condition is different 
for each consumer, it will be difficult to identify a specific factor for each one. 
However, it has been possible to find functional relationships in which the con-
sumption pattern will be characterized in the one hand by the type of substance 
abused, and in the other hand in the chain of functional background in the case of 
structural determinants, understood as “those circumstances in which people are 
born, grow, live, work and grow old as a result of the distribution of money, power 
and resources that will depend on the public policies adopted” [21] will play an 
important role.
Within each functional analysis of the behavior of drug abusers, they report in 
the background that the psychosocial determinants of addictions are in a cultural 
context that molds and shapes values in people, structuring their personality 
[22], which makes them more vulnerable to drug abuse in the short, medium or 
long term. The abuse of psychoactive substances operates as a positive reinforce-
ment before situations that, after their consumption, are gratifying because allow 
avoiding such a displeasing situation for a moment [23], a feeling of relaxation due 
to excessive work hours, the attachment to consumers receiving support from the 
same when there is no affection in the family or the ease of consumption in recre-
ational spaces such as bars, allows consumers to maintain unhealthy lifestyles [24].
The use of addictive substances is a complex behavior. To begin understand-
ing the different variables related, it is necessary to comprehend that people are 
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acquiring different behaviors based on learning, whether they are transmitted 
verbally, or if the person observes the behavior and then executes it [25].
As already mentioned, the etiology of the use of addictive substances is classi-
fied as multifactorial, because there is not only one factor determining an addic-
tive behavior. But it can be confirmed that the main factors related to a substance 
abuse problem are usually environmental, psychological and genetic [7, 26]. Since 
the interaction between genes and the environment can cause the expression of 
genes to undergo some modification, i.e., the individual experience of consumers 
produces changes in genes, which in turn influence memory, cognition, emotions 
and behavior, it can lead to a psychiatric disorder [27]. Sometimes, these genetic 
changes are not reversible and, unfortunately, not only influence the person who 
uses addictive substances, but also can be inherited. Consequently, substance 
abuse decreases the quality of life of the current and future generations. Among 
the environmental factors that lead to epigenetic changes, the following stand out: 
prenatal and postnatal factors, such as malnutrition, drug abuse of the parents dur-
ing pregnancy, abuse or stress [28]. To address the problem of substance abuse, the 
traditional medical model is insufficient to achieve adherence to treatment, because 
it only contemplates the biological factor. For that reason, it is relevant to focus 
the intervention towards a flexible treatment which adapts to the different factors 
influencing substance abuse. Interdisciplinary treatments have been reported to 
produce benefits to maintain or improve the quality of life of people with chronic 
degenerative diseases [29]. This style of treatment is characterized by relying on 
different areas of knowledge to improve or maintain effectively the health of people 
who consume addictive substances.
It is important to note that addictions treatment, although predominantly of a 
psychological type, must be duly complemented by medical specialists who focus 
their action not only on the pharmacological treatment of the addiction, while also 
emphasizing the timely diagnosis of conditions as well as the reference - counter-
reference of patients with conditions, associated with consumption, as this action 
will be decisive in the adherence that drug abusers will have to the medical treat-
ment and which, in turn, will promote their decision of abstinence [30] (Figure 1).
The definition based on the above, in which the strong relationship of the 
psychosocial determinants in addictions is observed, as well as some of the risk 
factors for medical and psychiatric comorbidities due to the use of addictive 
substances, becomes the implementation of treatments in the three levels of health 
care emergent; considering that entering in the topic of addictions is relatively 
new for health professionals, in addition to the fact that this interventions are not 
so simple, since treating an individual with addictions is carried out with marked 
parameters of preventive medicine and not only from the cure of the medical and 
psychiatric comorbidities that these consumptions cause. The treatment needs to be 
transdisciplinary and must include health protection, promotion and maintenance 
parameters, as well as the abstinence from substance abuse, since the user and 
abuse are committed in a multifactorial way.
Different treatments have been implemented in patients who have problems 
with the use of addictive substances. In the 60s, they were treated with psychologi-
cal therapies with the aim of modifying behavior based on punishment. These 
patients have a high rate of remission that over time presented a relapse [31]. 
Interventions via telephone, online and self-help manuals are also effective but over 
the months the relapse rate was significant [32].
With the advance of research and the development of psychology, programs 
were created that tried to improve treatments to increase adherence to treatment. 
To be able to work with the problem of additions it was done from the multidis-
ciplinary, involving different areas of knowledge in such a way that adequate 
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treatments will be provided to maintain or improve the quality of life of patients. 
The results are positive and supported by different investigations.
A Meta-analysis conducted by Schwartz [33] to a total of 416 clinical trials of 
different treatments for smokers and complemented by Becoña [34] recognizes the 
relevance of multimodal or multidisciplinary treatments to achieve abstinence, plac-
ing them as the most effective treatment. These results are supported by the work of 
Sanz et al. [35] who provided interdisciplinary treatment for people who use tobacco, 
granted psychological treatment, supported by nicotine replacement therapies, 
bupropion and other medical alternatives according to the patient’s characteristics. At 
the end of the treatment approximately 70% of the participants were in withdrawal.
It is suggested that integrated care may provide long-term benefits in terms of 
medical and wellness outcomes 6 months after treatment, for example Sterling 
[36] reports that in several studies conducted by Drug and Alcohol Research Team 
(DART) integrated care in the treatment of people with consumption of alcohol 
and other drugs and with medical or psychiatric conditions have 69% withdrawal 
compared to 55%. In a systematic review by Savic [37], it indicates that one of the 
objectives of comprehensive care is to improve the quality of life, incorporating the 
harm reduction strategy to achieve success. On the other hand, within the impor-
tant strategies for comprehensive care, staff training, training on alcohol and other 
drugs to doctors who have no attention to consumers is relevant, the reference to 
other instances for medical care is also indicated as An important strategy.
5. Harm reduction
If we examine the increase in the use of legal and illegal psychoactive substances 
during the last five decades, they have led us to the search for the best clinical 
Figure 1. 
Mexico presents inequality between its population and the social determinants allow us to understand the 
consumption of psychoactive substances in the country [18, 19].
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practices, in which their user will benefit from treatment and rehabilitation 
schemes to find the “cure”; that it is not only when consumption is abandoned in 
hospitalizations since, sadly for our health institutions, all the efforts made in these 
schemes do not contemplate the approaches for medical and psychiatric comorbidi-
ties derived from consumption, reducing the effectiveness from the discharge of the 
substance abusers, believing that the clinical setting that led them to this will not 
be repeated. Most of the time, when users are facing their daily life associated with 
consumption they restart the intake of psychoactive substances, discarding that all 
professional efforts in clinical treatments are extinguished with their relapse.
The World Drug Report [7] mentions the urgent need to redouble efforts in 
order to facilitate access to effective medical services, based on scientific evidence, 
in terms of prevention, treatment and care for people who consume psychoactive 
substances and desperately need them.
An example of these measures can be identified in the need to accelerate the 
accessibility to Hepatitis C treatment, a disease whose harmful health consequences 
for “drug” users are much greater than those of HIV/AIDS. It is very important to 
frame that in the latter, the transmission of the virus was one of the main diseases 
that emerged as an epidemic in the early 1980s through injected drugs (opiates) and 
at the end there will be the exchange of syringes in consumers of heroin in Liverpool 
or the decriminalization of the personal dose (amount without being lethal or 
illegal) in Holland in 1976 [38]. When total abstinence is not met, it is important to 
considered that one of the fundamental basis is to reduce or avoid further dam-
age [39] by decreasing morbidity-mortality and achieving family stability and 
the possibility of obtaining and keeping a job, family, besides to health, which is a 
priority [40].
Mexico has also implemented projects for harm reduction, such as the Syringe 
Program, as well as Methadone substitution therapy in Ciudad Juárez and Tijuana, 
managed by Non Governmental Organizations [41], which support people with 
physiological dependencies to prevent them from sharing the same syringe and 
avoid more complications.
In the context of demonstrating the benefits that can be obtained through 
multidisciplinary treatments, in which the aim is to achieve comprehensive health 
and improve the quality of life of the patients who consume any substance harmful 
to their health, which leads to non-communicable and infectious diseases also by 
the relationship of unhealthy behaviors. Harm Reduction is one element where it has 
been proven that it is not only about abstinence of substance abuse, it is also reduc-
ing the risks and damages associated to it.
Due to the relevance of the application of this strategy, we will now discern 
its meaning and scope in the current medicine. Reduction comes from the Latin 
reductio and means “action of returning something where or how it was.” Its lexical 
components are: the prefix re- (backwards); the word Damage (discomfort, pain, 
deterioration or injure) comes from the Latin damnum (condemnation, punish-
ment) [42]. For purposes of having an understanding updated and focused on the 
objective of finding a definition expressing the subject under study regarding the 
chore of health professionals’ work within the intervention, we find that reduction 
is everything that implies reducing the measure of a factor with actions leading to the 
original state or closest to it.
It should be mentioned that Harm Reduction differs from Risk Reduction, since 
the first is to avoid as much as possible the negative effects due to the use of sub-
stances, i.e., it pretends to reduce the harmful aspects that such practice may cause, 
promoting healthy and hygienic habits, so that the drug abusers will have an active 
participation in the event of consumption and their habits regarding such con-
sumption. While the second term becomes an educational-health activity involving 
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the problem regarding the consequences of drug abuse and the main population 
targeted is the one with no treatment related with its consumption [43].
The program for the patient with alcohol consumption started in 1974 at the 
Hospital General de México and in 1982 with the first Anti-Smoking Clinic (CCT), 
the latter program, ahead of their age, carried out multidisciplinary protocols 
addressed to the prevention, early and timely detection of diseases consequence 
of tobacco consumption, where therapeutic adherence played a very important 
role for the rehabilitation of the patient, as well as health education programs that 
will allow users know from their addiction to nicotine to their physical illness, in 
addition to a whole range of activities that will allow them modify their thoughts, 
behaviors and emotions that surround the consumption of the substance, achieving 
through this model the reduction of the damages [30]. The research carried out at 
the General Hospital of Mexico in which it compares two therapeutic techniques: 
cognitive restructuring and health education; the cessation obtained with the first 
was 52% while the second was 56%, important results because they indicate that 
by only applying health education the person can reach the cessation of the use of 
psychoactive substances [44].
In 2015 the treatment focused on all psychoactive substances, since the 
changes of the time were observed in the lifestyles of the population attending 
the anti-smoking clinic, because of which, from 2000 to 2010, 934 patients were 
studied demonstrating that 47% of users used more than one drug. Likewise, the 
inadequate processes were investigated in lifestyles where uncontrolled intake of 
soda and coffee was found between 64.1 and 68.4% [45] and sedentary life 61.8%. 
Other studies in this population also showed low level of assertiveness and social 
skills deficit [46]. Given these findings, the proposal is made through a holistic 
approach with the sum of the different medical specialties and subspecialties for the 
comorbidities by apparatus and system, as well as the psychological intervention, 
to abandon the different consumptions of psychoactive substances, widening their 
field of attention, monitoring the medical guidelines with therapeutic adherence, 
with a psychoeducational and active orientation in which it is intended to generate, 
strengthen and use the protective factors of each individual with therapies based on 
learning theories for the recovery of their physical and mental health and creating 
an intervention where the priority is still to reduce harm.
In the anti-smoking and other addictive substances clinics, the objective is for 
medical personnel to resume their activity in adherence to treatment as a funda-
mental tool for their work versus psychologists who are involved in the recovery and 
compliance of the treatment of medical or psychiatric comorbidities and not only 
work with cessation. Since we can observe that intrinsically the most important 
were bad habits in lifestyles, the discipline in self-care is responsible for playing a 
good role in their health and their execution is responsible for not consuming sub-
stances. Thus, within Harm Reduction Intervention proposed in a comprehensive 
care model, adherence to treatment has an important weight in the recovery of the 
person with substance abuse.
6. Adherence to treatment
Adherence to treatment allows patient to have greater control over chronic 
degenerative diseases. Commitment of patients, along with their motivation, is 
essential to continue such treatment, since it is relatively complex, prolonged and 
requires discipline, planning and adaptation to change. Chronic complications 
related to the use of psychoactive substances or drugs can be avoided or delayed if 
the person follows the instructions given by health specialists. The treatment that 
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patients with dependence receive focuses on the modification of addictive behaviors 
but unfortunately poor adherence is a very common situation and the high dropout 
rate is one of the factors that generate the greatest concern in the consumption of 
drugs [47].
The World Health Organization conducted an investigation to determine the 
level of adherence to treatment of people with chronic diseases living in devel-
oped countries. The results indicated that about only 50% of the people followed 
the indications and assumed that this deficiency would be greater in developing 
countries (such as Mexico) due to the scarcity of resources and inequities in access 
to medical care a fact still present nowadays [48].
The WHO [48] considers the lack of adherence to treatments and its negative 
clinical and economic consequences a priority public health issue. It also considers 
that compliance with treatments will result in a reduction of the overall health bud-
get, due to the reduction in the need for expensive interventions, such as frequent 
and prolonged hospitalizations, the unnecessary use of emergency services and 
costly intensive care services. If patients fail to have a good adherence, they will 
have great losses at a personal (physical and psychological), family and social level. 
In the United States, for example, poor adherence to taking the medication is related 
to 33–69% of hospitalizations [49]. An important point is that once again, the social 
determinants of health play an important role in allowing patients to adhere to their 
treatment, as well as on their socioeconomic status, public policies regarding social 
protection or the structure of the health system where they belong.
There are different definitions of adherence to treatment, one of the definitions 
that has been most widely accepted and which the WHO resumed in 2003 is the one 
proposed by Haynes [50] who defines it as “the degree to which a patient’s behavior 
in relation to taking medications, following a diet or changing lifestyle habits, 
coincides with the instructions provided by the doctor or healthcare staff.” It can be 
said that there is adherence when patients collaborate and participate proactively 
and voluntarily with their treatment, promoting better health conditions, which go 
beyond passive compliance with the indications [51].
Adherence is influenced by several psychosocial factors, such as beliefs, atti-
tudes, attributions, mental representation of the disease and social support [52, 53]. 
Adherence as a health behavior will be closely related to the general health values 
or motivation for health, it will also be modulated by the experimentation of risk or 
perceived vulnerability, the consideration of the severity of the disease and self-
efficacy [54] (Figure 2).
For the consumers to change their lifestyle, they first need to modify their belief 
system, since this is an important modulating factor in compliance with medical 
and/or health recommendations. The person follows the indications based on the 
considerations of his/her personal beliefs and on the perception of the origin of his/
her illness or the way he/she thinks he/she should face his/her health condition [55]. 
Patients have a representation of what a threat to their health means, their fears 
are concepts based on social learning in their relationships with others [56]. There 
are several sources that influence beliefs about their health: friends, family, media 
and information from other health professionals [57]. Patient beliefs regarding the 
treatment produce and maintain healthy behaviors. The specialist has to establish 
realistic expectations about the benefits patients will get when changing their 
lifestyle but take into consideration the time and effort required.
A strategic source of adherence to treatment is assertive communication, which 
occurs between the patient with addiction and the specialist. During the com-
munication exercise presented during the first approaches, especially during the 
first interview, it is essential to identify the level of predisposition that the person 
has to modify his/her addictive behavior. This level is directly related to the degree 
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of motivation of a patient, since it predicts whether consumption will remain the 
same or will change favorably [58]. To recognize and work on the motivation to 
change, the Transteoric Change Model and the Motivational Interview formulated 
by Prochaska and DiClemente [59] stand out in order to identify different levels 
of predisposition that a person can show -stages of change- when it is proposed to 
modify his/her addictive behavior [60]. Thus, favoring respect for the patient, his/
her beliefs and scale of values, trying to stimulate his/her motivation and favor his/
her positioning towards healthy habits, emphasizing his/her own point of view 
and his/her freedom to choose. Progressively increasing the willingness to change, 
becoming aware of the problem and developing the necessary strategies to over-
come it, including the skills to overcome contingencies and relapse. To go through 
the process of motivation to change in a stable and constant way, promoting his/
her level of self-efficacy and allowing him/her to have greater adherence. Besides, 
by emphasizing the discovery of his/her risk factors we will also work on protective 
factors, since both have a relevant role during the onset, development, maintenance 
and treatment of addictions [59].
7. Conclusion
In order to globally address the consumption of psychoactive substances, the 
clinical history is the indispensable information tool that will establish the meeting 
Figure 2. 
The treatment is directed towards the prevention of physical and psychiatric risk factors through a 
multidisciplinary intervention with the intervention of psychology, psychiatry and the different medical 
specialties [47].
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point with precision and the scientific, ethical, technological criteria that will be 
included in it, through their participation in its preparation between the different 
health professionals [61]. The integration will generate a unique file resulting in 
comprehensive management and attention, which serves as an effective com-
munication meeting point for the treatment and evolution of the disciplines that 
converge, as well as the homogenization of decision-making subsequent to the 
diagnosis established by the consumption of legal and illegal substances, and will 
influence with good practices on the diagnosis, treatment, rehabilitation, of the 
“drug” abusers and achieve healthy lifestyles, with the priority of enriching his/her 
quality of life, decreasing the risks, as well as motivating the user as far as possible 
to eradicate substance abuse through techniques for restructuring his/her beliefs, 
behaviors and emotions. Besides, the health professional will accept, in a more com-
mitted way, that the consumer may feel worried about his/her health even if he/she 
does not succeed or does not want to stop its consumption.
Finally, the first thing to conceive in the field of health, what we have been 
working on for decades, is to state that the harm reduction intervention focuses 
on the tertiary prevention framework, which is carried out once the problem has 
appeared and its objective is to avoid complications, reducing risks [62], transcend-
ing in the general improvement of patients (adherence to treatment/self-efficacy, 
self-care) and increasing their physical and psychological recovery by encourag-
ing abstinence and preventing relapses; reaching an approach that achieves the 
integral health of the users with interdisciplinary interventions, reducing the cost 
and increasing the benefit for the hospital users and their families, as well as for 
the psychological institution, reducing the cost and increasing the benefit for the 
hospital users and their families as well as for the institution.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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